Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab-based chemoimmunotherapy in early triple-negative breast cancer and its clinical significance.
AIMS To characterize the heterogeneity of pathological responses in the breast and regional lymph nodes after neoadjuvant pembrolizumab-based chemoimmunotherapy in early-stage triple-negative breast cancer (TNBC) and to explore their clinical implications. METHODS AND RESULTS A total of 203 patients with TNBC treated...